Navigate the Curis CRIS Stock Research Pages
Introduction - general company overview, financials, pipeline snapshot, upcoming catalysts
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
Debio0932 (aka CUDC-3205)
- Heat Shock Protein 90 (HSP90) inhibitor developed by Curis and licensed to privately held biotech Debiopharm
- Learn more about Debio0932 and other drugs in this class on my sister website HSP90 Central.